{
    "data": [
        {
            "id": "4225060",
            "type": "article",
            "attributes": {
                "publishOn": "2018-11-28T10:22:33-05:00",
                "isLockedPro": false,
                "commentCount": 30,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Nektar Currently Misunderstood",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104930",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "22203",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1952",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4225060-nektar-currently-misunderstood"
            }
        },
        {
            "id": "4221493",
            "type": "article",
            "attributes": {
                "publishOn": "2018-11-13T08:00:00-05:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Cancer Research Highlight: Nektar Posts An Encouraging SITC Report",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "93696",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "21704",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1952",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4221493-cancer-research-highlight-nektar-posts-encouraging-sitc-report"
            }
        },
        {
            "id": "4209887",
            "type": "article",
            "attributes": {
                "publishOn": "2018-10-04T12:20:55-04:00",
                "isLockedPro": false,
                "commentCount": 70,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Refuting Nektar's Apparent Response To Our Initial Report",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104808",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "20502",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1952",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4209887-refuting-nektars-apparent-response-to-initial-report"
            }
        },
        {
            "id": "4209320",
            "type": "article",
            "attributes": {
                "publishOn": "2018-10-02T08:15:06-04:00",
                "isLockedPro": false,
                "commentCount": 109,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pegging The Value Of NKTR-214 At Zero",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104808",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "20398",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1952",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4209320-pegging-value-of-nktrminus-214-zero"
            }
        },
        {
            "id": "4205537",
            "type": "article",
            "attributes": {
                "publishOn": "2018-09-11T10:46:13-04:00",
                "isLockedPro": false,
                "commentCount": 15,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "An Early Look At Nektar And Bristol-Myers Squibb's First Combination Phase 3 Trial",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104763",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "19607",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1952",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4205537-early-look-nektar-and-bristol-myers-squibbs-first-combination-phase-3-trial"
            }
        },
        {
            "id": "4204038",
            "type": "article",
            "attributes": {
                "publishOn": "2018-09-04T19:36:00-04:00",
                "isLockedPro": false,
                "commentCount": 19,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Nektar: A Rare Opportunity For Long-Term Investors",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56582",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "19363",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1952",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4204038-nektar-rare-opportunity-for-long-term-investors"
            }
        },
        {
            "id": "4202730",
            "type": "article",
            "attributes": {
                "publishOn": "2018-08-29T01:43:00-04:00",
                "isLockedPro": false,
                "commentCount": 23,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Nektar Therapeutics Offers A High-Potential But Controversial Pipeline",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24361",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "19161",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1952",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4202730-nektar-therapeutics-offers-high-potential-controversial-pipeline"
            }
        },
        {
            "id": "4191193",
            "type": "article",
            "attributes": {
                "publishOn": "2018-07-27T12:13:30-04:00",
                "isLockedPro": false,
                "commentCount": 12,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Rounds Report: Nektar Rallies Subsequent To An Overweight Rating By Piper Jaffray",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56582",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "17901",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1952",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4191193-rounds-report-nektar-rallies-subsequent-to-overweight-rating-piper-jaffray"
            }
        },
        {
            "id": "4184658",
            "type": "article",
            "attributes": {
                "publishOn": "2018-06-29T01:49:30-04:00",
                "isLockedPro": false,
                "commentCount": 20,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Rounds Report: Nektar Positioned As A Stellar Buying Opportunity Amid Strong Market Pessimism",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56582",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1952",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4184658-rounds-report-nektar-positioned-stellar-buying-opportunity-amid-strong-market-pessimism"
            }
        },
        {
            "id": "4180972",
            "type": "article",
            "attributes": {
                "publishOn": "2018-06-12T06:36:58-04:00",
                "isLockedPro": false,
                "commentCount": 22,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Nektar Therapeutics: In The Midst Of A Difficulty An Opportunity Arises",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56582",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "16247",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1952",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4180972-nektar-therapeutics-in-midst-of-difficulty-opportunity-arises"
            }
        },
        {
            "id": "4180354",
            "type": "article",
            "attributes": {
                "publishOn": "2018-06-08T11:58:23-04:00",
                "isLockedPro": false,
                "commentCount": 20,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Rounds Report: TransEnterix Moved North, FDA Due Diligence To Benefit Nektar",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56582",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "201042",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1952",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4180354-rounds-report-transenterix-moved-north-fda-due-diligence-to-benefit-nektar"
            }
        },
        {
            "id": "4179128",
            "type": "article",
            "attributes": {
                "publishOn": "2018-06-04T04:24:32-04:00",
                "isLockedPro": false,
                "commentCount": 62,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Nektar Therapeutics Preliminary Results At ASCO Means A Strong Push Into Phase 3 Studies",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "15939",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1952",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4179128-nektar-therapeutics-preliminary-results-asco-means-strong-push-phase-3-studies"
            }
        },
        {
            "id": "4179029",
            "type": "article",
            "attributes": {
                "publishOn": "2018-06-03T05:57:13-04:00",
                "isLockedPro": false,
                "commentCount": 15,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Rounds Report: Nektar Rallied Aggressively While Lexicon Experienced Significant Insider Purchases",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56582",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "15918",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1952",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4179029-rounds-report-nektar-rallied-aggressively-while-lexicon-experienced-significant-insider"
            }
        },
        {
            "id": "4174587",
            "type": "article",
            "attributes": {
                "publishOn": "2018-05-16T07:09:48-04:00",
                "isLockedPro": false,
                "commentCount": 19,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Nektar Therapeutics: Substantial Unlocked Value In The NKTR-358 Franchise",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56582",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "15243",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1952",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4174587-nektar-therapeutics-substantial-unlocked-value-in-nktrminus-358-franchise"
            }
        },
        {
            "id": "4162776",
            "type": "article",
            "attributes": {
                "publishOn": "2018-04-13T00:15:36-04:00",
                "isLockedPro": false,
                "commentCount": 12,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Nektar Therapeutics: What The REVEAL Study Entails",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56582",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "14134",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1952",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4162776-nektar-therapeutics-what-reveal-study-entails"
            }
        },
        {
            "id": "4161234",
            "type": "article",
            "attributes": {
                "publishOn": "2018-04-05T11:59:38-04:00",
                "isLockedPro": false,
                "commentCount": 15,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "BioSci Rounds Report: Unlocking Hidden Values In Omeros, Unum, And Nektar",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56582",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "197131",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1952",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4161234-biosci-rounds-report-unlocking-hidden-values-in-omeros-unum-and-nektar"
            }
        },
        {
            "id": "4153113",
            "type": "article",
            "attributes": {
                "publishOn": "2018-03-05T03:19:55-05:00",
                "isLockedPro": false,
                "commentCount": 12,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Nektar Therapeutics: The Gift That Keeps On Giving",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56582",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "12821",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1952",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4153113-nektar-therapeutics-gift-keeps-on-giving"
            }
        },
        {
            "id": "4147225",
            "type": "article",
            "attributes": {
                "publishOn": "2018-02-15T14:06:57-05:00",
                "isLockedPro": false,
                "commentCount": 14,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Nektar: About The Bristol Myers Deal",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101956",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1952",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4147225-nektar-bristol-myers-deal"
            }
        },
        {
            "id": "4146966",
            "type": "article",
            "attributes": {
                "publishOn": "2018-02-15T05:26:03-05:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Nektar Therapeutics: What The Bristol-Myers Squibb Deal For NKTR-214 Entails",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56582",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "12100",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1952",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4146966-nektar-therapeutics-what-bristol-myers-squibb-deal-for-nktrminus-214-entails"
            }
        },
        {
            "id": "4146945",
            "type": "article",
            "attributes": {
                "publishOn": "2018-02-15T02:59:17-05:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pay Your Money And Hold Your Breath",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20694",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1952",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4146945-pay-your-money-and-hold-your-breath"
            }
        },
        {
            "id": "4137115",
            "type": "article",
            "attributes": {
                "publishOn": "2018-01-12T05:05:51-05:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Nektar Therapeutics: Continued Upside In 2018",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24589",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "10681",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1952",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4137115-nektar-therapeutics-continued-upside-in-2018"
            }
        }
    ]
}